Search Results

You are looking at 1 - 10 of 23 items for :

  • "lapatinib" x
Clear All
Restricted access

Shireen Parsai, Jacob A. Miller, Aditya Juloori, Samuel T. Chao, Rupesh Kotecha, Alireza M. Mohammadi, Manmeet S. Ahluwalia, Erin S. Murphy, Gene H. Barnett, Michael A. Vogelbaum, Lilyana Angelov, David M. Peereboom and John H. Suh

systemic agents that have improved BBB penetration. Lapatinib is a small-molecule dual tyrosine kinase inhibitor targeted against the epidermal growth factor receptor (EGFR)1 and HER2 pathways. In 2007, lapatinib combined with capecitabine was approved for patients with HER2+ metastatic breast cancer who received prior therapy including anthracyclines, taxanes, and trastuzumab. 12 Due to its low molecular weight, it is hypothesized that lapatinib has improved BBB penetration in comparison to trastuzumab. In fact, in patients with HER2+ breast cancer brain metastases

Restricted access

Paul M. Arnold

research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies . Eur J Cancer 46 : 1204 – 1210 , 2010 3 Gril B , Palmieri D , Bronder JL , Herring JM , Vega-Valle E , Feigenbaum L , : Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain . J Natl Cancer Inst 100 : 1092 – 1103 , 2008 4 Lockman PR , Mittapalli RK , Taskar KS , Rudraraju V , Gril B , Bohn KA , : Heterogeneous blood-tumor barrier permeability determines drug efficacy

Restricted access

Brendan Fong, Garni Barkhoudarian, Patrick Pezeshkian, Andrew T. Parsa, Quinton Gopen and Isaac Yang

II clinical trials would still be warranted. Moreover, they hypothesized that there may be other molecular alterations that lead to vestibular schwannoma proliferation outside of EGFR receptors. 86 The benefits of these treatment options are that they can affect multiple tumors more easily than open surgery. Furthermore, there would be fewer toxic side effects than with cytotoxic agents, making such treatment options more suitable for long-term therapy. 20 , 39 Lapatinib Lapatinib is a dual inhibitor of EGFR and HER2 approved in 2007 by the US FDA. 73

Restricted access

Shigeo Matsunaga, Takashi Shuto, Nobutaka Kawahara, Jun Suenaga, Shigeo Inomori and Hideyo Fujino

, 18 , 22 The advantages that radiosurgery has over WBRT in the avoidance of cognitive decline are due to targeted radiation dose distributions, but the number of lesions treatable by the initial radiosurgical procedure is unclear, particularly if potential emergence of new lesions in the nonirradiated brain is considered. Another issue in the management of brain metastasis from breast cancer is the introduction of targeted systemic therapeutic agents such as trastuzumab and lapatinib. The survival of patients with breast cancer is affected by the histological

Restricted access

Melanie G. Hayden Gephart, Bonnie P. Taft, Anne-Katrin Giese, Raphael Guzman and Michael S. B. Edwards

of 2 pediatric patients with brainstem ependymoma in whom hypertension, seizures, and imaging consistent with PRES developed perioperatively. In both patients, the syndrome resolved after strict hypertension and seizure control. Case Reports Case 1 History This 4-year-old boy had a recurrent WHO Grade III anaplastic ependymoma with brainstem involvement. He had previously undergone 2 resections (2007 and 2008; with VP shunt placement in 2007), chemotherapy (2 cycles of bevacizumab and lapatinib per protocol CERN08–1, discontinued due to multiple

Restricted access

Ulaş Yener, Timucin Avsar, Emel Akgün, Aşkın Şeker, Yaşar Bayri and Türker Kılıç

, tyrosinekinase inhibitor, imatinib, targeting the specific growth factors and inhibiting both tumorigenesis and angiogenesis of schwannomas, might have a future role in the treatment of surgically and radiosurgically incurable VS, most often the NF2-associated lesions. 20 , 37 So, like some other novel molecular therapeutic options, such as bevacizumab, 31 , 63 , 64 trastuzumab, 12 , 15 erlotinib, 15 and lapatinib, 2 the possible first-line treatment field for imatinib is NF2 patients in whom all treatment modalities had been used but failed. 20 Conclusions The

Full access

Sherman C. Stein

JW : Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer . Cancer 115 : 489 – 498 , 2009 15 Maas AI , Menon DK , Lingsma HF , Pineda JA , Sandel ME , Manley GT : Re-orientation of clinical research in traumatic brain injury: report of an international workshop on comparative effectiveness research . J Neurotrauma 29 : 32 – 46 , 2012 16 Marko NF , Weil RJ : An introduction to comparative effectiveness research . Neurosurgery 70 : 425 – 434 , 2012 17 Murray GD , Barer D , Choi S

Full access

Rovel J. Colaco, Pierre Martin, Harriet M. Kluger, James B. Yu and Veronica L. Chiang

receiving ongoing systemic therapy for the presence of persistent systemic disease. TABLE 2. Systemic therapies according to category CT TT IT 5-Fluorouracil Bevacizumab Anti-CD 137 Abraxane Cetuximab Anti-CTLA-4 Adriamycin Dabrafenib Anti-PD-1 Capecitabine Dasatinib Interferon Carboplatin Erlotinib Interleukin 2 Cisplatin Everolimus Cyclophosphamide Gefitinib Dacarbazine Herceptin Etoposide Lapatinib Gemcitabine Letrozole Ifosfamide Panitumumab

Full access

Rohan Ramakrishna, Shaan M. Raza, Michael Kupferman, Ehab Hanna and Franco DeMonte

. References 1 Agulnik M , Cohen EW , Cohen RB , Chen EX , Vokes EE , Hotte SJ , : Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands . J Clin Oncol 25 : 3978 – 3984 , 2007 2 Airoldi M , Bumma C , Bertetto O , Riella AM , Gabriele P , Succo G , : Vinorelbine for recurrent adenocarcinomalike salivary gland malignancies . Eur J Cancer B Oral Oncol 32B : 213 – 214 , 1996

Restricted access

Courtney A. Jensen, Michael D. Chan, Thomas P. McCoy, J. Daniel Bourland, Allan F. deGuzman, Thomas L. Ellis, Kenneth E. Ekstrand, Kevin P. McMullen, Michael T. Munley, Edward G. Shaw, James J. Urbanic and Stephen B. Tatter

improved overall survival when added to some of the traditional systemic treatments for metastatic disease. Some of these systemic therapies, such as lapatinib for breast cancer and bevacizumab for breast, lung, and colorectal cancers, may affect the natural history of patients with brain metastases. Our data have shown a statistically significant improvement in overall survival of the population treated in the 3.0-T MR imaging era at our institution, which corresponds to the post–October 2005 treatment period, as compared with patients treated prior to this time period